Aligos Therapeutics stops development of CHB drug candidate ALG-010133
Aligos Therapeutics has stopped further development of ALG-010133, its STOPS drug candidate, in chronic hepatitis B (CHB) owing to futility. The California-based clinical stage biopharma company said that the decision has been driven by emerging data from the ALG-010133-101 phase 1 clinical trial that suggests there is no meaningful reduction of Hepatitis B surface antigen […]